Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

NSG-S mice for acute myeloid leukemia, yes. For myelodysplastic syndrome, no.

Griessinger E, Andreeff M.

Haematologica. 2018 Jun;103(6):921-923. doi: 10.3324/haematol.2018.193847. No abstract available.

2.

Intercellular mitochondria trafficking highlighting the dual role of mesenchymal stem cells as both sensors and rescuers of tissue injury.

Rodriguez AM, Nakhle J, Griessinger E, Vignais ML.

Cell Cycle. 2018;17(6):712-721. doi: 10.1080/15384101.2018.1445906.

3.

Dexamethasone in hyperleukocytic acute myeloid leukemia.

Bertoli S, Picard M, Bérard E, Griessinger E, Larrue C, Mouchel PL, Vergez F, Tavitian S, Yon E, Ruiz J, Delabesse E, Luquet I, Linares LK, Saland E, Carroll M, Danet-Desnoyers G, Sarry A, Huguet F, Sarry JE, Récher C.

Haematologica. 2018 Jun;103(6):988-998. doi: 10.3324/haematol.2017.184267. Epub 2018 Mar 8.

4.

Acute myeloid leukemia xenograft success prediction: Saving time.

Griessinger E, Vargaftig J, Horswell S, Taussig DC, Gribben J, Bonnet D.

Exp Hematol. 2018 Mar;59:66-71.e4. doi: 10.1016/j.exphem.2017.12.002. Epub 2017 Dec 15.

5.

Mitochondrial Transfer in the Leukemia Microenvironment.

Griessinger E, Moschoi R, Biondani G, Peyron JF.

Trends Cancer. 2017 Dec;3(12):828-839. doi: 10.1016/j.trecan.2017.10.003. Epub 2017 Nov 6. Review.

PMID:
29198439
6.

Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.

Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R, Bosc C, Sugita M, Stuani L, Fraisse M, Scotland S, Larrue C, Boutzen H, Féliu V, Nicolau-Travers ML, Cassant-Sourdy S, Broin N, David M, Serhan N, Sarry A, Tavitian S, Kaoma T, Vallar L, Iacovoni J, Linares LK, Montersino C, Castellano R, Griessinger E, Collette Y, Duchamp O, Barreira Y, Hirsch P, Palama T, Gales L, Delhommeau F, Garmy-Susini BH, Portais JC, Vergez F, Selak M, Danet-Desnoyers G, Carroll M, Récher C, Sarry JE.

Cancer Discov. 2017 Jul;7(7):716-735. doi: 10.1158/2159-8290.CD-16-0441. Epub 2017 Apr 17.

7.

Iron chelation: an adjuvant therapy to target metabolism, growth and survival of murine PTEN-deficient T lymphoma and human T lymphoblastic leukemia/lymphoma.

Benadiba J, Rosilio C, Nebout M, Heimeroth V, Neffati Z, Popa A, Mary D, Griessinger E, Imbert V, Sirvent N, Peyron JF.

Leuk Lymphoma. 2017 Jun;58(6):1433-1445. doi: 10.1080/10428194.2016.1239257. Epub 2016 Oct 13.

PMID:
27736268
8.

BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice.

Hamouda MA, Jacquel A, Robert G, Puissant A, Richez V, Cassel R, Fenouille N, Roulland S, Gilleron J, Griessinger E, Dubois A, Bailly-Maitre B, Goncalves D, Mallavialle A, Colosetti P, Marchetti S, Amiot M, Gomez-Bougie P, Rochet N, Deckert M, Avet-Loiseau H, Hofman P, Karsenti JM, Jeandel PY, Blin-Wakkach C, Nadel B, Cluzeau T, Anderson KC, Fuzibet JG, Auberger P, Luciano F.

J Exp Med. 2016 Aug 22;213(9):1705-22. doi: 10.1084/jem.20150983. Epub 2016 Jul 25.

9.

Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy.

Moschoi R, Imbert V, Nebout M, Chiche J, Mary D, Prebet T, Saland E, Castellano R, Pouyet L, Collette Y, Vey N, Chabannon C, Recher C, Sarry JE, Alcor D, Peyron JF, Griessinger E.

Blood. 2016 Jul 14;128(2):253-64. doi: 10.1182/blood-2015-07-655860. Epub 2016 Jun 2.

10.

Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients.

Griessinger E, Anjos-Afonso F, Vargaftig J, Taussig DC, Lassailly F, Prebet T, Imbert V, Nebout M, Vey N, Chabannon C, Filby A, Bollet-Quivogne F, Gribben JG, Peyron JF, Bonnet D.

Cancer Res. 2016 Apr 15;76(8):2082-6. doi: 10.1158/0008-5472.CAN-15-2063. Epub 2016 Mar 9.

11.

APOBEC3A is implicated in a novel class of G-to-A mRNA editing in WT1 transcripts.

Niavarani A, Currie E, Reyal Y, Anjos-Afonso F, Horswell S, Griessinger E, Luis Sardina J, Bonnet D.

PLoS One. 2015 Mar 25;10(3):e0120089. doi: 10.1371/journal.pone.0120089. eCollection 2015.

12.

A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia.

Saland E, Boutzen H, Castellano R, Pouyet L, Griessinger E, Larrue C, de Toni F, Scotland S, David M, Danet-Desnoyers G, Vergez F, Barreira Y, Collette Y, Récher C, Sarry JE.

Blood Cancer J. 2015 Mar 20;5:e297. doi: 10.1038/bcj.2015.19.

13.

Cross-sectional comparison of small animal [18F]-florbetaben amyloid-PET between transgenic AD mouse models.

Brendel M, Jaworska A, Grießinger E, Rötzer C, Burgold S, Gildehaus FJ, Carlsen J, Cumming P, Baumann K, Haass C, Steiner H, Bartenstein P, Herms J, Rominger A.

PLoS One. 2015 Feb 23;10(2):e0116678. doi: 10.1371/journal.pone.0116678. eCollection 2015.

14.

L-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia.

Rosilio C, Nebout M, Imbert V, Griessinger E, Neffati Z, Benadiba J, Hagenbeek T, Spits H, Reverso J, Ambrosetti D, Michiels JF, Bailly-Maitre B, Endou H, Wempe MF, Peyron JF.

Leukemia. 2015 Jun;29(6):1253-66. doi: 10.1038/leu.2014.338. Epub 2014 Dec 8.

PMID:
25482130
15.

A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: a new tool to decipher their chemoresistance and self-renewal mechanisms.

Griessinger E, Anjos-Afonso F, Pizzitola I, Rouault-Pierre K, Vargaftig J, Taussig D, Gribben J, Lassailly F, Bonnet D.

Stem Cells Transl Med. 2014 Apr;3(4):520-9. doi: 10.5966/sctm.2013-0166. Epub 2014 Feb 3.

16.

Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation.

Miraki-Moud F, Anjos-Afonso F, Hodby KA, Griessinger E, Rosignoli G, Lillington D, Jia L, Davies JK, Cavenagh J, Smith M, Oakervee H, Agrawal S, Gribben JG, Bonnet D, Taussig DC.

Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13576-81. doi: 10.1073/pnas.1301891110. Epub 2013 Jul 30.

17.

Pharmacological inhibition of carbonic anhydrase XII interferes with cell proliferation and induces cell apoptosis in T-cell lymphomas.

Lounnas N, Rosilio C, Nebout M, Mary D, Griessinger E, Neffati Z, Chiche J, Spits H, Hagenbeek TJ, Asnafi V, Poulsen SA, Supuran CT, Peyron JF, Imbert V.

Cancer Lett. 2013 Jun 1;333(1):76-88. doi: 10.1016/j.canlet.2013.01.020. Epub 2013 Jan 21.

PMID:
23348702
18.

Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis.

Quintana-Bustamante O, Lan-Lan Smith S, Griessinger E, Reyal Y, Vargaftig J, Lister TA, Fitzgibbon J, Bonnet D.

Leukemia. 2012 Jul;26(7):1537-46. doi: 10.1038/leu.2012.38. Epub 2012 Feb 10.

19.

Aerodynamically assisted bio-jetting of hematopoietic stem cells.

Griessinger E, Jayasinghe SN, Bonnet D.

Analyst. 2012 Mar 21;137(6):1329-33. doi: 10.1039/c2an16027g. Epub 2012 Feb 2.

PMID:
22297267
20.

Frequency of leukemic initiating cells does not depend on the xenotransplantation model used.

Vargaftig J, Taussig DC, Griessinger E, Anjos-Afonso F, Lister TA, Cavenagh J, Oakervee H, Gribben J, Bonnet D.

Leukemia. 2012 Apr;26(4):858-60. doi: 10.1038/leu.2011.250. Epub 2011 Sep 16. No abstract available.

21.

Heterogeneous sensitivity of human acute myeloid leukemia to β-catenin down-modulation.

Gandillet A, Park S, Lassailly F, Griessinger E, Vargaftig J, Filby A, Lister TA, Bonnet D.

Leukemia. 2011 May;25(5):770-780. doi: 10.1038/leu.2011.17. Epub 2011 Feb 22.

22.

β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells.

Yeung J, Esposito MT, Gandillet A, Zeisig BB, Griessinger E, Bonnet D, So CW.

Cancer Cell. 2010 Dec 14;18(6):606-18. doi: 10.1016/j.ccr.2010.10.032.

23.

Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells.

Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, Chen JL, Keller AM, Joffre O, Zelenay S, Nye E, Le Moine A, Faure F, Donckier V, Sancho D, Cerundolo V, Bonnet D, Reis e Sousa C.

J Exp Med. 2010 Jun 7;207(6):1261-71. doi: 10.1084/jem.20092618. Epub 2010 May 17.

24.

"Microenvironmental contaminations" induced by fluorescent lipophilic dyes used for noninvasive in vitro and in vivo cell tracking.

Lassailly F, Griessinger E, Bonnet D.

Blood. 2010 Jul 1;115(26):5347-54. doi: 10.1182/blood-2009-05-224030. Epub 2010 Mar 9.

25.

Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction.

Taussig DC, Vargaftig J, Miraki-Moud F, Griessinger E, Sharrock K, Luke T, Lillington D, Oakervee H, Cavenagh J, Agrawal SG, Lister TA, Gribben JG, Bonnet D.

Blood. 2010 Mar 11;115(10):1976-84. doi: 10.1182/blood-2009-02-206565. Epub 2010 Jan 6.

26.

Preclinical targeting of NF-kappaB and FLT3 pathways in AML cells.

Griessinger E, Frelin C, Cuburu N, Imbert V, Dageville C, Hummelsberger M, Sirvent N, Dreano M, Peyron JF.

Leukemia. 2008 Jul;22(7):1466-9. doi: 10.1038/sj.leu.2405102. Epub 2008 Jan 31. No abstract available.

PMID:
18239622
27.

Pharmacological targeting of NF-kappaB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells.

Lagadec P, Griessinger E, Nawrot MP, Fenouille N, Colosetti P, Imbert V, Mari M, Hofman P, Czerucka D, Rousseau D, Berard E, Dreano M, Peyron JF.

Br J Cancer. 2008 Jan 29;98(2):335-44. doi: 10.1038/sj.bjc.6604082. Epub 2008 Jan 8.

28.

AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells.

Griessinger E, Imbert V, Lagadec P, Gonthier N, Dubreuil P, Romanelli A, Dreano M, Peyron JF.

Leukemia. 2007 May;21(5):877-85. Epub 2007 Mar 1.

PMID:
17330097
29.

Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells.

Frelin C, Imbert V, Griessinger E, Peyron AC, Rochet N, Philip P, Dageville C, Sirvent A, Hummelsberger M, Bérard E, Dreano M, Sirvent N, Peyron JF.

Blood. 2005 Jan 15;105(2):804-11. Epub 2004 Sep 28.

30.

AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-alpha in Jurkat leukemic cells.

Frelin C, Imbert V, Griessinger E, Loubat A, Dreano M, Peyron JF.

Oncogene. 2003 Nov 6;22(50):8187-94.

PMID:
14603259
31.

[Fighting cancer via NF-kappa B inhibition].

Sirvent N, Imbert V, Frelin C, Griessinger E, Peyron JF.

Arch Pediatr. 2003 Jul;10(7):632-4. Review. French. No abstract available.

PMID:
12907074

Supplemental Content

Loading ...
Support Center